About Platelet-activating factor acetylhydrolase IB subunit alpha2
Platelet-activating factor acetylhydrolase IB subunit alpha2 (PAFAH1B2) is a protein
from Homo sapiens identified by UniProt accession
P68402, 229 residues long.
MolForge cross-references it against 0 known binders and
217 disease associations.
Target properties
| Protein name | Platelet-activating factor acetylhydrolase IB subunit alpha2 |
|---|
| UniProt accession | P68402 |
|---|
| Gene | PAFAH1B2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 229 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (217)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- blood protein measurement · score 0.30
- soluble transferrin receptor measurement · score 0.28
- protein measurement · score 0.22
- self reported educational attainment · score 0.21
- Calcium channel blocker use measurement · score 0.21
- high density lipoprotein cholesterol measurement · score 0.19
- pancreatic ductal adenocarcinoma · score 0.19
- pancreatic carcinoma · score 0.19
- acute myeloid leukemia · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P68402-F1 | alphafold | PREDICTED | 93.90 | — |
Amino-acid sequence (229 residues)
MSQGDSNPAA IPHAAEDIQG DDRWMSQHNR FVLDCKDKEP DVLFVGDSMV QLMQQYEIWR ELFSPLHALN FGIGGDTTRH VLWRLKNGEL ENIKPKVIVV WVGTNNHENT AEEVAGGIEA IVQLINTRQP QAKIIVLGLL PRGEKPNPLR QKNAKVNQLL KVSLPKLANV QLLDTDGGFV HSDGAISCHD MFDFLHLTGG GYAKICKPLH ELIMQLLEET PEEKQTTIA
Explore Platelet-activating factor acetylhydrolase IB subunit alpha2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets